Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and shor...

Annovis Bio -0.40%

Annovis Bio

ANVS

12.46

-0.40%

Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via